Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
View ORCID ProfileLuis Rosero-Bixby
doi: https://doi.org/10.1101/2021.11.08.21266087
Luis Rosero-Bixby
Universidad de Costa Rica, Centro Centroamericano de Población (CCP)
Roles: Emeritus Professor
Data Availability
All data produced in the present work are contained in the manuscript (Appendix table)
Posted November 09, 2021.
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence
Luis Rosero-Bixby
medRxiv 2021.11.08.21266087; doi: https://doi.org/10.1101/2021.11.08.21266087
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (692)
- Anesthesia (185)
- Cardiovascular Medicine (2781)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12436)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4303)
- Geriatric Medicine (397)
- Health Economics (706)
- Health Informatics (2778)
- Health Policy (1031)
- Hematology (371)
- HIV/AIDS (883)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4080)
- Nursing (218)
- Nutrition (605)
- Oncology (2158)
- Ophthalmology (609)
- Orthopedics (253)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (481)
- Pediatrics (1152)
- Primary Care Research (475)
- Public and Global Health (6682)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (196)
- Urology (172)